Neuroprotective Effect of a Novel Soluble Guanylate Cyclase Activator Runcaciguat in Diabetic and Ischemic Retinopathy
Soluble guanylate cyclase (sGC) subunits are expressed in retinal vascular and neuronal cells. Runcaciguat activates sGC impaired by oxidative stress in vitro and in vivo. Runcaciguat improves retinal neuronal function and morphology in rat models of ischemia-reperfusion and streptozotocin-induced diabetes. Restoring sGC activity is a novel therapeutic target for early diabetic retinopathy.
Authors
- Lingli Zhou (ORCID: https://orcid.org/0000-0002-9321-9348)
- James Guerra
- Yangyiran Xie (ORCID: https://orcid.org/0000-0001-9194-2439)
- William Schubert
- Elia J. Duh (ORCID: https://orcid.org/0000-0003-1917-373X)
- S.X. Wu
- Hongkwan Cho (ORCID: https://orcid.org/0000-0002-1409-5886)
- Qiaoyan Hui
- Fabio Baschiera
- Lijuan Wu (ORCID: https://orcid.org/0000-0002-5761-5140)
- Joseph Mertz (ORCID: https://orcid.org/0000-0003-3158-809X)
- Carsten Terjung (ORCID: https://orcid.org/0000-0002-8202-9231)
- Grace Lee (ORCID: https://orcid.org/0000-0001-7892-2871)
- Zhenhua Xu (ORCID: https://orcid.org/0000-0002-3415-0133)
- Khaled Nassar (ORCID: https://orcid.org/0000-0003-4974-3828)
Institutions
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Diabetes
- Published
- 2025-04-18
- DOI
- https://doi.org/10.2337/db24-0739
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71